Nurix Therapeutics (NRIX) Equity Ratio (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Equity Ratio data on file, last reported at 0.76 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.76, down 3.32% year-over-year; the trailing twelve-month figure through Feb 2026 was 0.76 (down 3.32% YoY), and the FY2025 annual result was 0.78, down 0.56% from the prior year.
• Equity Ratio slipped to 0.76 in Q1 2026 per NRIX's latest filing, from 0.78 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.79 in Q4 2024 and troughed at 0.54 in Q1 2024.
• A 5-year average of 0.72 and a median of 0.74 in 2023 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio retreated 27.11% in 2024, then soared 44.88% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.73 in 2022, then slipped by 22.63% to 0.56 in 2023, then soared by 39.64% to 0.79 in 2024, then retreated by 0.56% to 0.78 in 2025, then fell by 3.44% to 0.76 in 2026.
• Business Quant data shows NRIX's Equity Ratio at 0.76 in Q1 2026, 0.78 in Q4 2025, and 0.71 in Q3 2025.